GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
GenFlow Biosciences
1,413 followers
7h
GenFlow Biosciences (LSE: GENF) (OTCQB: GENFF) is thrilled to announce its partnership with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants 🧬
"The two research programs are a part of a broader innovation partnership that the Walloon Government has launched, dedicated to Advanced Therapy Medicinal Products (ATMPs). The partnership boasts a substantial budget of 81 million euros, a mix of 60% public funding and 40% private contributions from various companies, spread over three years. This initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia and the Public Service of Wallonia, representing a significant commitment to advancing medical research and development in the region."
Read more about the exciting new venture here: hTtps://loom.ly/dF-wrxc
#ageing #longevity #healthspan #smallcap
LONDON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, in collaboration with Revatis SA and EXO Biologics, is proud to announce the initiation of two significant research programs backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium. Both of these strategic initiatives will strengthen Genflow’s position at the forefront ageing-related research, and its mission to improve the health and well-being of older adults.
And this one? :-)
9.3218849
VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES
CA - 17.11.2022
Int.Class
C12N 15/113
Appl.No 3218849
Applicant UNIVERSITY OF ROCHESTER
Inventor GORBUNOVA, VERA
The present invention relates to an isolated nucleic acid molecule encoding a variant of sirtuin 6 (SIRT6) having at least 75% identity with sequence SEQ ID NO: 1, the variant having at least one mutation selected in the group comprising or consisting of a N308K substitution and a A313S substitution with respect to sequence SEQ ID NO: 1. The invention provides means for the regulation of ageing, and/or senescence, and/or lifespan in an individual. The invention further provides means for the repair of double strand breaks in a cell. Finally, the invention also provides means for the prevention and/or the treatment of an age-related disease.
Don’t forget Vera’s patent too: US 63/188,573 14.05.2021
12 months since a crucial patent application, not just for Genflow but a breakthrough for gene therapy and longevity research according to Eric, which could add massive value if awarded. It can take up to 2 years for approval, but the US Patent Office can award within 12 months if accelerated, and so news at anytime which would be truly transformational for all concerned. Gla :-)
"Genflow has expanded its intellectual property portfolio with a provisional patent application focusing on the SIRT6 gene editing. If granted, this patent could mark a significant breakthrough in gene therapy and longevity research."
1.20230018934
METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS
US - 19.01.2023
Int.Class
A61K 48/00
Appl.No 17865688
Applicant GENFLOW BIOSCIENCES SRL
Inventor Eric LEIRE
Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.
3p plus next stop with more of the same tomorrow with any luck. Gla holders...more good news at anytime. :-)
Great to see a buzz again after a long period of no news! Eric is a genius
Closing on days high! Tomorrow looks fruitful
Let the substantial free grants do the talking!
A lot of ramping from Earl. Calm down please
Hear hear Earl!
LTH should be grateful we turn up rallying the troops. Reap the rewards! If the price goes up selll if it drops once we leave buy back, the aim of the game is to make dollar bills. End of story.
On that note we look to be closing strongly!
Only low life attacks The hidden gem finders like Gordonbennett, Earl of AIM
cowards never give any good tips, the ones does gets slated.
pathetic to say Gordonbennett is a ramper
the guy posting information to the adults, make up your mind.
Remember wee lol, Gordon, everyone knows your a ramper.
You won't be here tomorrow that's my guess
Money munch those final results of recent studies must be imminent too! Expected end of 2023, dotting the I’d and crossing the ts
Yup most missed late RNS, some taking places now!
Remember last year we hit 5.5p on a mention of a US Listing, todays news means cash in the hopper which imo beats the former
Still very much under the radar and still cheap as chips, the timing of today's news missed by many and so just the start of some serious UPside, especially as more positive newsflow is very likely in the near term pipeline. Gla holders :--)
Come on big fella, blow off some steam into close
Aiming for a top of the leaderboard close now
Jeff Bazoz wants this tech!!!!
Read here
https://www.theguardian.com/business/2023/nov/05/british-biotech-races-uss-buff-billionaires-for-secret-of-eternal-youth?CMP=share_btn_link
This news is not known to many yet, once they come from work and see this, tommorow we should see bigger buys
maybe Fund managers will start to buy for their clients also
Going now Earl nice and tight
Intraday RNS caught most out! We haven’t even broke recent price levels yet
Gordonbennett
this news is not known to many yet, once they come from work and see this, tommorow we should see bigger buys
maybe Fund managers will start to buy for their clients also
Think they are right Earl, huge grant and non dilutive means the sp should only go one way from here! 4-5p in t he next few sessions seems doable!
One of the world’s richest man looking at this tech!!!
to live younger and younger, longevity of life
at the moment only billionaires and wealthy people spend millions to keep younger.
this is about to change for the mass market.
https://www.theguardian.com/business/2023/nov/05/british-biotech-races-uss-buff-billionaires-for-secret-of-eternal-youth?CMP=share_btn_link